ANI Pharmaceuticals Azioni (NASDAQ: ANIP)

ANI Pharmaceuticals

ANI PHARMACEUTICALS INC

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Pharmacy,,Pills,And,Box,With,Healthcare,Store,,Shelf,And,Prescription

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ANIP

OMER

Queste 3 azioni sanitarie possono rappresentare un&#39;opportunità di investimento. Ecco le migliori scelte per gli investitori.

Azioni sanitarie sottovalutate: scopri le opportunità di investimento

ANI Pharmaceuticals Inc

Press Releases

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

General

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Legal

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

Earnings

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

CGON

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ATAI Life Sciences

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

BGM Group

Bausch Health Companies Inc. Common Stock

Bausch Health Companies

Belite Bio, Inc - American Depositary Shares

Belite Bio

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pharvaris

Perrigo

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Xeris Biopharma Holdings, Inc. - Common Stock

Comments

ANI Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO